The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-na ïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score

Conclusions AAP significantly improved outcomes in mCRPC patients compared with prednisone alone regardless of baseline pain and PSA level, and GS at primary diagnosis with no significant differences between observed treatment effects in groups 1 and 2. Patient summary Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis. This post hoc analysis of the pivotal COU-AA-302 study shows that abiraterone acetate plus prednisone significantly improves outcomes in patients with metastatic castration-resistant prostate cancer regardless of baseline characteristics. The observed treatment effects in patients at an early versus advanced disease stage were not significantly different.
Source: European Urology - Category: Urology & Nephrology Source Type: research